Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics

SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bisp...

2024-10-09 23:00 1273

Baird Medical Lists in the U.S. on the Nasdaq Exchange

Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker FORT MILL, S.C., Oct. 9, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading micro...

2024-10-09 20:30 1419

Baird Medical Lists in the U.S. on the Nasdaq Exchange

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking

TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO:Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a master agreement signed on April 22, 2024 by Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:...

2024-10-09 10:00 1280

Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials

KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. ( https://www.regenephro.co.jp/ ) is excited to announcethat the company has successfully developed a funding plan of total approximately17 million dollar (2.5 billion JPY) in new Series B funding and ...

2024-10-09 07:39 2369

Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials

MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections

FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused byMycobacterium abscessus (Mab),...

2024-10-08 13:38 990

MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections

Sciwind Biosciences Announces Oral Presentation on Oral GLP-2 Research Progress at the 32nd United European Gastroenterology Week (UEG Week 2024)

BEIJING and HANGZHOU, China, Oct. 7, 2024 /PRNewswire/ -- The 32nd United European Gastroenterology Week (UEG Week 2024) will take place inVienna, Austria , fromOctober 12 to 15, 2024. UEG Week is the largest gastroenterology conference inEurope and one of the leading meetings worldwide. It brings...

2024-10-08 10:00 1251

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead a global clinical study to evaluate the therapeutic poten...

2024-10-08 08:00 1351

TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218

* TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) * The first patient with head and neck squamous cell carcinoma was dosed in the Phase 2a clinical trial of TU2218 *...

2024-10-04 20:00 1647

WELLlife COVID-19/Influenza A&B Home Test on Sale for Amazon Prime Day

Standfirst: Welllife, a Flu home test in addition to COVID-19 BOLINGBROOK, Ill., Oct. 3, 2024 /PRNewswire/ -- WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing this flu season. The WELLlife COVID-19/Influenza A&B...

2024-10-03 21:00 1172

WELLlife COVID-19/Influenza A&B Home Test on Sale for Amazon Prime Day

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia

HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...

2024-09-30 15:00 1063

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- OnSeptember 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr.Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along with leading Chinese onco-h...

2024-09-30 13:48 1000

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

HONG KONG, Sept. 30, 2024 /PRNewswire/ -- September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA) for a new indication: cadonilimab in combination with...

2024-09-30 13:42 990

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

* Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of$850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire...

2024-09-30 13:00 922

SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies

NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approv...

2024-09-29 21:00 1266

IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting

SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentati...

2024-09-29 21:00 2209

New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs

SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building atShanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for...

2024-09-28 20:00 2934

New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs

111, Inc. Announces Receipt of Notification from Nasdaq

SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced it has received a...

2024-09-28 05:00 2902

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentat...

2024-09-27 15:41 1092

$IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting$

Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria

SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN...

2024-09-26 15:10 1386

The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA

CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug A...

2024-09-25 21:18 1771

1 ... 3 4 567 8 9 ... 126